Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Print1
- Article Type
- Research Support, U.S. Gov't, Non-P.H.S.1
- Research Support, U.S. Gov't, P.H.S.1
- Result From
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- J Pharmacol Exp Ther1
Search Results
Sort by
- ArticleJacoby JH, Shabshelowitz H, Fernstrom JD, Wurtman RJ.J Pharmacol Exp Ther. 1975 Nov;195(2):257-64.Brain tryptophan and 5-hydroxyindole levels are elevated in rats given methiothepin, a neuroleptic that appears to block serotonin receptors. The rise in brain tryptophan probably results from a drug-induced increase in the ratio of plasma tryptophan concentration to the sum of the neutral amino acids in plasma that compete with tryptophan for uptake into the brain; this change in the plasma amino acid pattern may be mediated in part by a methiothepin-induced rise in plasma insulin. Methiothepin also decreases the proportion of circulating tryptophan that is bound to albumin. Unlike exogenous tryptophan, methiothepin fails to increase 5-hydroxyin-doles caudal to the site of a spinal cord transection. Therefore, the mechanism by which methiothepin elevates 5-hydroxyindole levels involves not only increased brain tryptophan levels but also continued impulse flow along serotonergic neurons.